Sign in
Taking people in United StatesPhase 1

Tests a B7-H3 targeted T-cell therapy in children with solid tumors

Tests engineered immune T cells in young patients with relapsed or hard-to-treat solid tumors.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Status
Recruiting
Phase
Phase 1
People taking part
48 people, planned
Started
6 Jul 2022
Expected to end
1 Mar 2028
Type of study
Interventional
Treatments tested
  • Fludarabine
  • Cyclophosphamide
  • MESNA
  • B7-H3 CAR T cells
Record updated
19 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people up to 21 years old whose B7-H3-positive solid tumor has come back or did not respond to first treatment. It tests B7-H3-CAR T cells made from the person's own blood.

Age
Up to 21 years old.
Sex
All sexes can join.
Disease stage
A solid tumor that is B7-H3 positive and can be measured. The disease has come back or did not respond after standard first-line therapy.
Earlier treatment
Must have had standard first-line therapy without lasting success. Must have recovered from serious (grade III-IV) non-blood side effects of earlier treatment.
Biomarker or test result
The tumor must be B7-H3 positive, with an H-score of 100 or more on a standard tissue stain test (IHC).

Main reasons for not taking part

  • Known primary immunodeficiency
  • History of HIV infection
  • Severe, uncontrolled infection
  • History of allergic reaction to products containing mouse protein
  • Rapidly progressing disease

The registry criteria, word for word

Show all 44 criteriaShow less

Who can take part

  • Procurement and T-cell production eligibility*
  • *a previously collected, autologous leukapheresis product can be used for T-cell production
  • Age ≤21 years old
  • B7-H3+ solid tumor with measurable disease; B7-H3 expression will be evaluated by standard immunohistochemistry (IHC) using a previously obtained biopsy; a tumor is considered B7-H3 positive with an H-score ≥100
  • Estimated life expectancy of >12 weeks
  • Karnofsky or Lansky (age-dependent) performance score ≥50
  • For females of child bearing age:
  • Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
  • Not lactating with intent to breastfeed
  • Meets eligibility criteria to undergo autologous apheresis, or have previously undergone autologous apheresis
  • Treatment eligibility
  • Age ≤21 years old
  • B7-H3+ solid tumor with measurable disease
  • Evidence of relapsed or refractory disease after standard first-line therapy
  • Estimated life expectancy of >8 weeks
  • Karnofsky or Lansky (age-dependent) performance score≥50
  • Echocardiogram with a ventricular ejection fraction
  • >40%; or shortening fraction ≥25%
  • Adequate renal function defined as creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if < 2 years of age)
  • Adequate pulmonary function defined as pulse oximetry ≥92% on room air or forced vital capacity (FVC) ≥50% of predicted value
  • Total Bilirubin ≤3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
  • Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
  • Hemoglobin≥ 7g/dL (can be transfused)
  • Platelet count >50,000/uL (can be transfused)
  • Absolute neutrophil count (ANC) ≥ 1000/uL
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • For females of child bearing age:
  • Not pregnant with negative serum pregnancy test within 7 days prior to enrollment
  • Not lactating with intent to breastfeed
  • If sexually active, agreement to use birth control until 3 months after T-cell infusion. Male partners should use a condom
  • Available autologous transduced T-cell product that has met GMP release criteria
  • Agreement to participate in long-term follow-up protocol for patients, who have received genetically modified cell products

Who cannot take part

  • Receiving systemic steroid therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to B7-H3-CAR T-cell infusion
  • Receiving systemic therapy in the 14 days prior to CAR T-cell infusion, which will interfere with the activity of the B7-H3-CAR product (in the opinion of the study PIs)
  • Known HIV positivity
  • Severe intercurrent bacterial, viral or fungal infection (e.g. active hepatitis B or C infection or adenovirus infection)
  • History of hypersensitivity reactions to murine protein-containing products
  • Rapidly progressive disease (in the opinion of the study PIs)
  • History of HIV infection
  • Severe, uncontrolled intercurrent bacterial, viral or fungal infection
  • History of hypersensitivity reactions to murine protein-containing products
  • Rapidly progressing disease (in the opinion of the study PIs)
  • Known primary immunodeficiency
  • Known primary immunodeficiency

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Chris DeRenzo, MDTaking people

About the trial

What the trial wants to find out

3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive solid tumors.

Read full original descriptionShow less

Primary objective

To determine the safety of one intravenous infusion of autologous, B7-H3-CAR T cells in patients (≤ 21 years) with recurrent/refractory B7-H3+ solid tumors after lymphodepleting chemotherapy

Secondary objective

To evaluate the antitumor activity of B7-H3-CAR T cells

Exploratory objectives

* To evaluate the tumor environment after treatment with B7-H3-CAR T cells * To assess the immunophenotype, clonal structure and endogenous repertoire of B7-H3-CAR T cells and unmodified T cells * To characterize the cytokine profile in the peripheral blood after treatment with B7-H3-CAR T cells

The group in the trial

  • Treatment PhaseOther group

    During the treatment phase, the participant receives an infusion of the B7-H3-CAR T cells that were made in the Collection and Manufacturing Phase. Chemotherapy is given for several days prior to the cellular infusion. Patients are then monitored for possible side effects, as well as effects of the treatment on their cancer.

    Treatment: Fludarabine, Cyclophosphamide, MESNA, and B7-H3 CAR T cells

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Plain-language title
Tests a B7-H3 targeted T-cell therapy in children with solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
19 May 2026